Oncotelic Therapeutics (OTCQB: OTLC) and Sapu Nano announced that Chief Executive Officer Vuong Trieu will present the Deciparticle nanomedicine platform at the BIO International Convention 2026 in San Diego. The presentation will focus on the development of ultra-small nanomedicine formulations designed to enable intravenous administration of highly water-insoluble therapeutics. The Deciparticle platform utilizes proprietary amphiphilic polymer systems capable of forming sub-20 nanometer particles for oncology and other therapeutic applications.
The companies plan to showcase development progress across multiple Deciparticle programs, including Sapu006, a polysorbate-free intravenous docetaxel formulation moving into Phase 1b clinical evaluation, and Sapu003, an intravenous everolimus nanomedicine program currently in a global Phase 1b clinical trial. The presentation will also highlight the integration of artificial intelligence and knowledge-organization technologies into formulation development and translational oncology workflows through the PDAOAI platform.
This announcement underscores the potential of the Deciparticle platform to address significant challenges in drug delivery, particularly for poorly soluble drugs that are difficult to administer intravenously. By enabling the use of established therapeutics in new formulations, Oncotelic and Sapu Nano aim to improve therapeutic index and patient outcomes. The inclusion of AI-driven tools further enhances the efficiency of formulation development and biomarker discovery.
Oncotelic Therapeutics is a clinical-stage biopharmaceutical company focused on oncology and immunotherapy, with a mission to address high-unmet-need cancers and rare pediatric indications. The company leverages the expertise of its CEO, Dr. Vuong Trieu, who has filed over 500 patent applications and holds 75 issued patents. Oncotelic also utilizes its proprietary AI-enabled PDAOAI platform to support research and regulatory processes.
For more information, the full press release is available at https://ibn.fm/RUG7m. Updates on OTLC can be found at https://ibn.fm/OTLC.
The presentation at BIO International Convention 2026 is expected to attract attention from industry leaders and researchers interested in nanomedicine and targeted drug delivery. The success of Sapu006 and Sapu003 could pave the way for broader applications of the Deciparticle platform across multiple therapeutic areas.
